Last edition
News about "JB Pharma"
JB Pharma Releases its Third Sustainability Report FY24
JB Pharma’s third sustainability report highlights the company’s achievements in reducing its environmental impact and improving resource efficiency.
JB Pharma | 22/10/2024 | By Aishwarya | 133
JB Pharma to acquire the entire Razel (Rosuvastatin) franchise for Rs. 314 crores
The acquisition marks JB Pharma’s entry into the ‘Statin’ segment which is the largest group in the cardiac therapy. Razel ranks among the top 10 brands in the Rosuvastatin molecule category in the country <br />
JB Pharma | 15/12/2022 | By Sudeep Soparkar | 349
JB Pharma commits to ESG in its maiden Sustainability Report
The sustainability report is for the year FY 2021 – 2022
JB Pharma | 17/10/2022 | By Sudeep Soparkar | 309
JB Pharma initiates #Heart2HeartChallengeIndia
Aims to spread awareness about heart health amongst the masses
JB Pharma | 22/09/2022 | By Sudeep Soparkar | 472
IQVIA Market Reflection Report - JB Pharma
IQVIA Market Reflection Report pins JB Pharma as the fastest growing Pharma Company with a growth rate of over 20% for the month of August 2022
JB Pharma | 22/09/2022 | By Sudeep Soparkar | 559
JB Pharma acquires four paediatric brands from Dr Reddy's Laboratories
The total covered market size of four brands – Z&D, Pedicloryl, Pecef and Ezinapi combined is Rs 1800 crores
JB Pharma | 01/07/2022 | By Sudeep Soparkar | 324
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy